Scientists believe a pharmaceutical version of a naturally occurring peptide could protect lungs from coronavirus


While the pharmaceutical industry has mainly focused on developing antiviral drugs that can fight off coronavirus infections and vaccines, one biotech firm is working on a treatment that would protect a patient's lungs from COVID-19's worst effects, Stat News reports.
Scientists now have a clear sense that the virus enters a person's system through ACE2, an enzyme commonly found on the surface of lung cells. One of ACE2's jobs is to prevent inflammation, but when it's interrupted (as it is in coronavirus patients), it can no longer keep a peptide that constricts blood vessels, known as angiotensin II, in check. Normally, ACE2 would fend off angiotensin II by converting it to angiotensin-(1-7), another peptide that relaxes the vessels and reduces inflammation, protecting people from blood clots and oxidation, which some COVID-19 patients have suffered from.
Two scientists, Concepción Peiró, a professor of pharmacology at the Autonomous University of Madrid, and Salvador Moncada, a professor of clinical pharmacology at the University of Manchester, hypothesized that boosting angiotensin-(1-7) could protect patients' lungs, while the immune system took care of the virus on its own. Upon learning this, Rick Franklin, the CEO of Constant Therapeutics, informed the Peiró and Moncada of his company's pharmaceutical version of the naturally-occurring angiotensin-(1-7), and Columbia University is now launching a trial for the drug.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
As usual, the testing period will prove tricky, but there's a growing consensus that combating the unopposed angiotensin II could be a "good technique" in trying to protect patients' lungs from the virus, even if it doesn't stave off the infection itself. Read more at Stat News.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
How to go on your own Race Across the World
The Week Recommends The BBC hit show is inspiring fans to choose low-budget adventures
-
The rebirth of Monaco
The Week Recommends The billionaires' playground is pulling out all the stops to entice Gen Z
-
Sudoku hard: June 3, 2025
The Week's daily hard sudoku puzzle
-
Breakthrough gene-editing treatment saves baby
speed read KJ Muldoon was healed from a rare genetic condition
-
Sea lion proves animals can keep a beat
speed read A sea lion named Ronan beat a group of college students in a rhythmic dance-off, says new study
-
Humans heal much slower than other mammals
Speed Read Slower healing may have been an evolutionary trade-off when we shed fur for sweat glands
-
Novel 'bone collector' caterpillar wears its prey
Speed Read Hawaiian scientists discover a carnivorous caterpillar that decorates its shell with the body parts of dead insects
-
Scientists find hint of alien life on distant world
Speed Read NASA's James Webb Space Telescope has detected a possible signature of life on planet K2-18b
-
Katy Perry, Gayle King visit space on Bezos rocket
Speed Read Six well-known women went into lower orbit for 11 minutes
-
Scientists map miles of wiring in mouse brain
Speed Read Researchers have created the 'largest and most detailed wiring diagram of a mammalian brain to date,' said Nature
-
Scientists genetically revive extinct 'dire wolves'
Speed Read A 'de-extinction' company has revived the species made popular by HBO's 'Game of Thrones'